B.Tech, M.Tech, M.Sc, MBA Preferably with B.Pharm or Masters. Should possess keen interest and drive for promoting technology innovation/ entrepreneurship.
Graduate in Biological Sciences from a recognised University with two years experience from a recognized institution OR Masters degree M.Sc. Biotechnology in the Biological Sciences from a recognised university.
Personnel handling this profile will be responsible for performing reactions as per the requirement of the project. They are also responsible for documenting the observations in relevant note books. They are to follow instructions from the supervisor and work in a group to accomplish the tasks in a timely and efficient manner.
Candidates who have completed their courses and have their Provisional Certificate (mandatory), Degree Certificate/ All Semester Marksheets ONLY considered.
Must not hold a bachelors or specialist/master’s degree and must have completed or be completing a program qualifying for higher education admission in their country during the 2025-2026 academic year
A toxic protein forms dynamic pores in the membranes of brain cells – and that may be the key to understanding how Parkinson’s disease develops. This is the conclusion of a new study from Aarhus University, where researchers have developed an advanced method to track molecular attacks in real time.
Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.
Novartis has entered into an agreement to acquire Tourmaline Bio, Inc, a New York-based, publicly traded clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease.